109 related articles for article (PubMed ID: 3074627)
1. The effect of thymic substances on T circulating cells of patients treated for Hodgkin's disease.
Chisesi T; Capnist G; Rancan L; Pellizzari G; Vespignani M
J Biol Regul Homeost Agents; 1988; 2(4):193-8. PubMed ID: 3074627
[TBL] [Abstract][Full Text] [Related]
2. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
[TBL] [Abstract][Full Text] [Related]
3. Effects of thymopoietin pentapeptide (TP-5) on in vitro and in vivo IgE production by atopic dermatitis cell subsets.
Cooper KD; Kang K; Hanifin JM
Diagn Immunol; 1983; 1(3):211-5. PubMed ID: 6388971
[TBL] [Abstract][Full Text] [Related]
4. Partial review of immunotherapeutic pharmacology in stem cell transplantation.
Bierman PJ; Abe F; Buyukberber S; Ino K; Talmadge JE
In Vivo; 2000; 14(1):221-36. PubMed ID: 10757081
[TBL] [Abstract][Full Text] [Related]
5. Biological, histological, and clinical impact of preoperative IL-2 administration in radically operable gastric cancer patients.
Romano F; Cesana G; Berselli M; Gaia Piacentini M; Caprotti R; Bovo G; Uggeri F
J Surg Oncol; 2004 Dec; 88(4):240-7. PubMed ID: 15565596
[TBL] [Abstract][Full Text] [Related]
6. Cyclic delivery of MOPP and ABVD combinations in Stage IV Hodgkin's disease: rationale, background studies, and recent results.
Bonadonna G; Santoro A; Bonfante V; Valagussa P
Cancer Treat Rep; 1982 Apr; 66(4):881-7. PubMed ID: 6176323
[TBL] [Abstract][Full Text] [Related]
7. The effect of thymopentin treatment on the relapse rate in frequently relapsing herpes simplex virus infections.
Haneke E; Bolla K; Degreef H; Djawari D; Demaubeuge J; Molin L; Panconesi E; Schöpf E; Stengel R; Stingl G
Int J Clin Pharmacol Res; 1984; 4(6):439-43. PubMed ID: 6085327
[TBL] [Abstract][Full Text] [Related]
8. Improvement of natural killer activity and of T cells after thymopoietin pentapeptide therapy in a patient with severe combined immunodeficiency.
Fiorilli M; Sirianni MC; Pandolfi F; Quinti I; Tosti U; Aiuti F; Goldstein G
Clin Exp Immunol; 1981 Aug; 45(2):344-51. PubMed ID: 7032772
[TBL] [Abstract][Full Text] [Related]
9. Effects of a synthetic extract (thymopentin) on the immune system of lepromatous leprosy patients.
Munno I; Pellegrino NM; Fumo G; Barbieri G; Polimeno G; de Filippis V; Jirillo E
Cytobios; 1987; 52(210-211):167-73. PubMed ID: 3123147
[TBL] [Abstract][Full Text] [Related]
10. Effect of thymectomy on peripheral lymphocyte subsets in myasthenia gravis: selective effect on T-cells in patients with thymic atrophy.
Haynes BF; Harden EA; Olanow CW; Eisenbarth GS; Wechsler AS; Hensley LL; Roses AD
J Immunol; 1983 Aug; 131(2):773-7. PubMed ID: 6408188
[TBL] [Abstract][Full Text] [Related]
11. Age-related thymic activity in adults following chemotherapy-induced lymphopenia.
Sfikakis PP; Gourgoulis GM; Moulopoulos LA; Kouvatseas G; Theofilopoulos AN; Dimopoulos MA
Eur J Clin Invest; 2005 Jun; 35(6):380-7. PubMed ID: 15948899
[TBL] [Abstract][Full Text] [Related]
12. Randomized study for the treatment of adult advanced Hodgkin's disease: mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) versus lomustine, vinblastine, and prednisone.
Liebman HA; Hum GJ; Sheehan WW; Ryden VM; Bateman JR
Cancer Treat Rep; 1983 May; 67(5):413-9. PubMed ID: 6342771
[TBL] [Abstract][Full Text] [Related]
13. The risk of acute leukemia in patients treated for Hodgkin's disease is significantly higher aft [see bined modality programs than after chemotherapy alone and is correlated with the extent of radiotherapy and type and duration of chemotherapy: a case-control study.
Brusamolino E; Anselmo AP; Klersy C; Santoro M; Orlandi E; Pagnucco G; Lunghi F; Maurizi-Enrici R; Baroni CD; Lazzarino M; Mandelli F; Bernasconi C
Haematologica; 1998 Sep; 83(9):812-23. PubMed ID: 9825578
[TBL] [Abstract][Full Text] [Related]
14. ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results.
Bonadonna G; Bonfante V; Viviani S; Di Russo A; Villani F; Valagussa P
J Clin Oncol; 2004 Jul; 22(14):2835-41. PubMed ID: 15199092
[TBL] [Abstract][Full Text] [Related]
15. Activities of purine nucleotide metabolizing enzymes in human thymocytes and peripheral blood T lymphocytes: in vitro effect of thymic hormones.
Ramagopal S; Reem GH
Thymus; 1982 May; 4(3):163-72. PubMed ID: 6287680
[TBL] [Abstract][Full Text] [Related]
16. Long-term complications of MOPP chemotherapy in patients with Hodgkin's disease.
Cunningham J; Mauch P; Rosenthal DS; Canellos GP
Cancer Treat Rep; 1982 Apr; 66(4):1015-22. PubMed ID: 7074629
[TBL] [Abstract][Full Text] [Related]
17. Usefulness of monoclonal antibodies in the diagnosis and monitoring of patients with primary immunodeficiencies: combined experience in three clinical immunology centers.
Aiuti F; Quinti I; Seminara R; Sirianni MC; Vierucci A; Abo T; Cooper MD
Diagn Immunol; 1983; 1(3):188-94. PubMed ID: 6388970
[TBL] [Abstract][Full Text] [Related]
18. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
[TBL] [Abstract][Full Text] [Related]
19. Thymopentin treatment of herpes simplex infections. An open, monitored, multicenter study.
DeMaubeuge J; Haneke E; Djawari D; Wolff K; Stingl G; Molin L; Schöpf E; Stengel R; Degreef H; Panconesi E
Surv Immunol Res; 1985; 4 Suppl 1():30-6. PubMed ID: 2863860
[TBL] [Abstract][Full Text] [Related]
20. Differential recovery of circulating T cell subsets after nodal irradiation for Hodgkin's disease.
Haas GS; Halperin E; Doseretz D; Linggood R; Russell PS; Colvin R; Barrett L; Cosimi AB
J Immunol; 1984 Feb; 132(2):1026-30. PubMed ID: 6361130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
